Dataset Information

Deciphering cellular processes responding to lethality of 17β-estradiol by quantitative phosphoproteomics

ABSTRACT: 17β-estradiol (E2) is an important endocrine hormone underlying mammalian body, which participates in the regulatory of physiological functions of reproductive system, mammary gland, bone and cardiovascular, et.al. Paradoxically, despite the physiological actions of endogenous E2 (0.2-1.0 nmol/L), numerous clinical and experimental studies demonstrated that high-dose E2 treatment could cause tumor regression and exert pro-apoptotic actions in multiple cells, but the underlying mechanism is still undescribed. Especially, little information of cellular processes responding to lethality of 17β-estradiol is available. In the present work, we attempted to characterize the cellular processes responding to high-dose (mol/L) E2 treatment by quantitative phosphoproteomics to help understand the regulatory mechanism of E2 induced cell death. Therefore, to analyze the cell phenotype induced by high-dose (umol/L) E2, cell counting kit-8 assay (CCK8), cell cytotoxicity analysis by trypan blue staining and microscopy imaging were first performed on HeLa cells following 1-10 mol/L E2 or dimethyl sulfoxide (DMSO) treatment for 1-3 days. As a result, E2 was found to inhibit cell proliferation and induce cell death in a dose-dependent and time-dependent fashion. Specially, in comparison with DMSO-treated HeLa cell samples, 5 umol/L E2 treatment for 2 days resulted in > 74% of growth inhibition and about 50% of cell death, which was employed for following quantitative phosphoproteomic analysis. To investigate the intracellular cellular processes responding to high-dose (umol/L) E2 treatment, solid phase extraction (SPE)-based immobilized titanium ion affinity chromatography (Ti-IMAC) phosphopeptide enrichment method coupled with data independent acquisition (DIA)-based quantitative proteomics was employed for in-depth screening of high-dose E2 regulated phosphorylation sites. As a result, more than 10000 phosphorylation sites were identified from the E2 and DMSO treated HeLa cell samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Among these phosphorylation sites, in comparison with the DMSO-treated cell samples, 5 umol/L E2 treatment caused an increase of 537 phosphorylation sites on 372 proteins and a decrease of 387 phosphorylation sites on 256 proteins with a threshold of p-value < 0.01 and |fold change|≥2. Totally 924 phosphorylation sites on 599 proteins were significantly regulated by high-dose (umol/L) E2, which were then performed for enrichment analysis. In addition, 453 phosphorylation sites on 325 proteins were found to be identified in only E2 or DMSO treated cell samples. These phosphorylation sites probably be phosphorylated or de-phosphoylated responding to high-dose E2 stimulation, which likely be regulated by high-dose (umol/L) E2 and were also performed for enrichment analysis in parallel. Taken together, 1218 phosphorylation sites on 741 proteins were significantly regulated by high-dose E2.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Hailin Wang

PROVIDER: PXD043554 | JPOST Repository | Fri Jul 05 00:00:00 BST 2024

REPOSITORIES: jPOST

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	HF_LYN1_DIA_phos2nd_HeLa_5E2_bio1.raw	Raw
	HF_LYN1_DIA_phos2nd_HeLa_5E2_bio2.raw	Raw
	HF_LYN1_DIA_phos2nd_HeLa_5E2_bio3.raw	Raw
	HF_LYN1_DIA_phos2nd_HeLa_5E2_bio4.raw	Raw
	HF_LYN1_DIA_phos2nd_HeLa_Vehicle_bio1.raw	Raw

Items per page:

1 - 5 of 9

Similar Datasets

Project description:The growing number of particle treatment facilities worldwide and patients treated with particles instead of X-rays marks the upcoming rearrangement of modern radiotherapy. Especially for tumors being difficult to access and for tumors that are resistant to conventional X-ray treatment particle radiotherapy is a beneficial technology. At the Heidelberg Ion Beam Therapy Center (HIT) patients are treated with this technology since 2009 as it offers clear benefits. Contrary to X-rays, which show an exponential dose decrease (after reaching electron equilibrium) with increasing tissue depth, charged particles deposit most of their energy to a small region within the tissue with a sharp dose fall-off after the so-called Bragg peak. This precise dose localization enables further dose escalation within the tumor while sparing healthy tissue. Besides physical advantages, particle radiotherapy offers additional biological advantages. In radiobiology, the term relative-biological effectiveness (RBE) is defined as the ratio of X-rays dose to an alternative irradiation modality dose which produce the same biological effect (e.g. survival or number of DSBs). While protons have a relative biological effectiveness (RBE) comparable to X-rays, carbon ions are more effective in inducing DNA damage(1, 2) and are therefore especially useful for radioresistant tumors. This is due to the fact, that carbon ions induce clustered and direct DNA damage, which is considered to be less dependent on cell cycle stage, oxygen level, genetic background and hinders DNA repair mechanisms(3–6). Nevertheless, their exact mode of action and cellular mechanisms are largely unknown. We show the first comprehensive proteomic and phosphoproteomic study elucidating the cellular response to treatment with protons, carbon ions and X-rays. We found that 2h after treatment with these radiations negligible regulation occurred at protein expression level. But 181 phosphorylation sites were deregulated by ionizing radiation contributing mainly to DNA damage response functionalities. Interestingly we found 55 phosphorylation sites being differentially regulated between the radiations. Here, we observed protons and carbon ions producing equal cellular response whereas X-rays show altered regulation for certain phosphorylation sites. A subset of 28 phosphorylation sites being involved in the DNA damage response or differentially regulated between the ionizing radiations was selected for result confirmation.

Project description:Toxicity testing is vital to protect human health from exposure to toxic chemicals in the environment. Furthermore, combining novel cellular models with molecular profiling technologies, such as metabolomics can add new insight into the molecular basis of toxicity and provide a rich source of biomarkers that are urgently required in a 21st Century approach to toxicology. We have used an NMR-based metabolic profiling approach to characterise for the first time the metabolome of the RPTEC/TERT1 cell line, an immortalised non-tumour human renal epithelial cell line that recapitulates phenotypic characteristics that are absent in other in vitro renal cell models. RPTEC/TERT1 cells were cultured with either the dosing vehicle (DMSO) or with exposure to one of six compounds (nifedipine, potassium bromate, monuron, D-mannitol, ochratoxin A and sodium diclofenac), several of which are known to cause renal effects. Aqueous intracellular and culture media metabolites were profiled by 1H NMR spectroscopy at 6, 24 and 72 hours of exposure to a low effect dose (IC10). We defined the metabolome of the RPTEC/TERT1 cell line and used a principal component analysis approach to derive a panel of key metabolites, which were altered by chemical exposure. By considering only major changes (+/- 1.5 fold change from control) across this metabolite panel we were able to show specific alterations to cellular processes associated with chemical treatment. Our findings suggest that metabolic profiling of RPTEC/TERT1 cells can report on the effect of chemical exposure on multiple cellular pathways at low-level exposure, producing different response profiles for the different compounds tested with a greater number of major metabolic effects observed in the toxin treated cells. Importantly, compounds with established links to chronic renal toxicity produced more diverse and severe perturbations to the cellular metabolome than non-toxic compounds in this model. As these changes can be rationalised with the different pharmacological and toxicity profiles of the chemicals it is suggested that metabolic profiling in the RPTEC/TERT1 model would be useful in investigating the mechanism of action of toxins at a low dose.

Dataset Information

Deciphering cellular processes responding to lethality of 17β-estradiol by quantitative phosphoproteomics

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets